Ahmed M. E. Abdalla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ahmed M. E. Abdalla has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Yu Miao
NHC Key Laboratory of Diagnosis and Therapy of Gastrointestinal Tumor, Gansu Provincial Hospital
5 shared publications- Chenxi Ouyang
Department of Vascular Surgery, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College
4 shared publications - Guang Yang
Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, China
3 shared publications Chenxi Ouyang
Department of Vascular Surgery, Fuwai Hospital, National Center for Cardiovascular Disease Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
2 shared publications- Lixia Huang
Hubei Key Laboratory of Purification and Application of Plant Anti-Cancer Active Ingredients, School of Chemistry and Life Sciences, Hubei University of Education, Wuhan 430205, China
2 shared publications - Ning Meng
School of Biological Sciences and Technology, University of Jinan
2 shared publications
Latest Publications
- 20 August 2026
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 44 (16) , 7537-7551
Elucidating the mechanism of ADAM10/PD-L1 interaction in pancreatic adenocarcinoma cell lines using cellular and computational analyses
1. Cancer immunotherapy is a therapeutic method for fighting cancer by stimulating or generating an immune response against tumors (Taefehshokr et al., 2022). Diverse cancer immunotherapeutic metho...
- 20 August 2026
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 44 (16) , 7537-7551
Elucidating the mechanism of ADAM10/PD-L1 interaction in pancreatic adenocarcinoma cell lines using cellular and computational analyses
1. Cancer immunotherapy is a therapeutic method for fighting cancer by stimulating or generating an immune response against tumors (Taefehshokr et al., 2022). Diverse cancer immunotherapeutic metho...
- 13 May 2026
- Published by Taylor & Francis in International Reviews of Immunology
- Vol. 45 (5) , 1-16
Upregulation of ADAM10 reinforces CD8 + T cells toward exhaustion in the TME
The human genome encodes 22 distinct A disintegrin and metalloproteases (ADAMs), which are required for various developmental activities, including spermatogenesis, the central nervous system, and ...
- 13 May 2026
- Published by Taylor & Francis in International Reviews of Immunology
- Vol. 45 (5) , 1-16
Upregulation of ADAM10 reinforces CD8 + T cells toward exhaustion in the TME
The human genome encodes 22 distinct A disintegrin and metalloproteases (ADAMs), which are required for various developmental activities, including spermatogenesis, the central nervous system, and ...
- 19 February 2026
- Published by Wiley in Immunology
- Vol. 178 (3) , 387-400
Strategies of AI ‐Driven CAR ‐T Cell Therapy Towards Solid Tumours
Chimeric antigen receptor (CAR)‐T cell immunotherapy shows significant success in hematologic malignancies. However, it faces critical challenges in solid tumours, such as suppressive tumour microenvironment (TME) and antigenic heterogeneity, highlighting the urgent need for effective and safe CAR products. The integration of artificial intelligence (AI) into CAR‐T cell immunotherapy offers exceptional opportunities to improve its therapeutic efficacy. More specifically, this paper highlights the transformative role of AI in addressing key challenges that impede the success of CAR‐T cell therapy in solid tumours, including assisting in CAR design and manufacturing process, identifying novel CAR‐targeted genes, and detecting cell heterogeneity in solid tumours. We remain optimistic about AI‐driven strategies for enhancing CAR T‐cell persistence, trafficking, and visualisation in the TME. In addition, we highlight the current challenges and prospects for advancing AI‐driven CAR‐T cell therapies.
- 19 February 2026
- Published by Wiley in Immunology
- Vol. 178 (3) , 387-400
Strategies of AI ‐Driven CAR ‐T Cell Therapy Towards Solid Tumours
Chimeric antigen receptor (CAR)‐T cell immunotherapy shows significant success in hematologic malignancies. However, it faces critical challenges in solid tumours, such as suppressive tumour microenvironment (TME) and antigenic heterogeneity, highlighting the urgent need for effective and safe CAR products. The integration of artificial intelligence (AI) into CAR‐T cell immunotherapy offers exceptional opportunities to improve its therapeutic efficacy. More specifically, this paper highlights the transformative role of AI in addressing key challenges that impede the success of CAR‐T cell therapy in solid tumours, including assisting in CAR design and manufacturing process, identifying novel CAR‐targeted genes, and detecting cell heterogeneity in solid tumours. We remain optimistic about AI‐driven strategies for enhancing CAR T‐cell persistence, trafficking, and visualisation in the TME. In addition, we highlight the current challenges and prospects for advancing AI‐driven CAR‐T cell therapies.
- 17 October 2024
- Published by Wiley in Immunology & Cell Biology
- Vol. 102 (10) , 907-923
ADAM10 modulates the efficacy of T‐cell‐mediated therapy in solid tumors
T‐cell‐mediated therapeutic strategies are the most potent effectors of cancer immunotherapy. However, an essential barrier to this therapy in solid tumors is disrupting the anti‐cancer immune response, cancer‐immunity cycle, T‐cell priming, trafficking and T‐cell cytotoxic capacity. Thus, reinforcing the anti‐cancer immune response is needed to improve the effectiveness of T‐cell‐mediated therapy. Tumor‐associated protease ADAM10, endothelial cells (ECs) and cytotoxic CD8+ T cells engage in complex communication via adhesion, transmigration and chemotactic mechanisms to facilitate an anti‐cancer immune response. The precise impact of ADAM10 on the intricate mechanisms underlying these interactions remains unclear. This paper broadly explores how ADAM10, through different routes, influences the efficacy of T‐cell‐mediated therapy. ADAM10 cleaves CD8+ T‐cell‐targeting genes and impacts their expression and specificity. In addition, ADAM10 mediates the interactions of adhesion molecules with T cells and influences CD8+ T‐cell activity and trafficking. Thus, understanding the role of ADAM10 in these events may lead to innovative strategies for advancing T‐cell‐mediated therapies.
- 17 October 2024
- Published by Wiley in Immunology & Cell Biology
- Vol. 102 (10) , 907-923
ADAM10 modulates the efficacy of T‐cell‐mediated therapy in solid tumors
T‐cell‐mediated therapeutic strategies are the most potent effectors of cancer immunotherapy. However, an essential barrier to this therapy in solid tumors is disrupting the anti‐cancer immune response, cancer‐immunity cycle, T‐cell priming, trafficking and T‐cell cytotoxic capacity. Thus, reinforcing the anti‐cancer immune response is needed to improve the effectiveness of T‐cell‐mediated therapy. Tumor‐associated protease ADAM10, endothelial cells (ECs) and cytotoxic CD8+ T cells engage in complex communication via adhesion, transmigration and chemotactic mechanisms to facilitate an anti‐cancer immune response. The precise impact of ADAM10 on the intricate mechanisms underlying these interactions remains unclear. This paper broadly explores how ADAM10, through different routes, influences the efficacy of T‐cell‐mediated therapy. ADAM10 cleaves CD8+ T‐cell‐targeting genes and impacts their expression and specificity. In addition, ADAM10 mediates the interactions of adhesion molecules with T cells and influences CD8+ T‐cell activity and trafficking. Thus, understanding the role of ADAM10 in these events may lead to innovative strategies for advancing T‐cell‐mediated therapies.
- 20 February 2024
- Published by Wiley in Cell Biochemistry and Function
- Vol. 42 (2) , e3955
CAR‐T cell therapeutic avenue for fighting cardiac fibrosis: Roadblocks and perspectives
Heart diseases remain the primary cause of human mortality in the world. Although conventional therapeutic opportunities fail to halt or recover cardiac fibrosis, the promising clinical results and therapeutic efficacy of engineered chimeric antigen receptor (CAR) T cell therapy show several advancements. However, the current models of CAR‐T cells need further improvement since the T cells are associated with the triggering of excessive inflammatory cytokines that directly affect cardiac functions. Thus, the current study highlights the critical function of heart immune cells in tissue fibrosis and repair. The study also confirms CAR‐T cell as an emerging therapeutic for treating cardiac fibrosis, explores the current roadblocks to CAR‐T cell therapy, and considers future outlooks for research development.
- 20 February 2024
- Published by Wiley in Cell Biochemistry and Function
- Vol. 42 (2) , e3955
CAR‐T cell therapeutic avenue for fighting cardiac fibrosis: Roadblocks and perspectives
Heart diseases remain the primary cause of human mortality in the world. Although conventional therapeutic opportunities fail to halt or recover cardiac fibrosis, the promising clinical results and therapeutic efficacy of engineered chimeric antigen receptor (CAR) T cell therapy show several advancements. However, the current models of CAR‐T cells need further improvement since the T cells are associated with the triggering of excessive inflammatory cytokines that directly affect cardiac functions. Thus, the current study highlights the critical function of heart immune cells in tissue fibrosis and repair. The study also confirms CAR‐T cell as an emerging therapeutic for treating cardiac fibrosis, explores the current roadblocks to CAR‐T cell therapy, and considers future outlooks for research development.
- 19 October 2020
- Published by SAGE Publications in Journal of Bioactive and Compatible Polymers
- Vol. 35 (6) , 504-516
Polyethylenimine-coated gold-magnetic nanoparticles for ADAM10 siRNA delivery in prostate cancer cells
For an effective medical application of therapeutic siRNA, a safe and an efficient delivery system are required. Herein, magnetic nanoparticles (MNPs) have been successfully used as siRNA delivery vehicles. Firstly, MNPs were coated with gold (Au) nanoparticles and then capped with PEI. To improve the biocompatibility of nanoparticles, hyaluronic acid (HA) was coated onto the surface of PEI-Au/Fe nanoparticles. The prepared HA-PEI-Au/Fe3O4 nanoparticles were characterized and found to be uniform and well segregated in TEM analysis. FTIR analysis confirmed that HA was successfully conjugated to PEI. The polymer content in these nanoparticles was relatively higher than PEG coated nanoparticles. Cell viability assay demonstrated that the nanoparticles were relatively biocompatible in nature. ADAM10 siRNA was loaded into the HA-PEI-Au/Fe3O4 nanoparticles and cytotoxicity to prostate cancer (PC3) cells was analyzed. The results indicate that ADAM10 siRNA loaded HA-PEI-Au/Fe3O4 suppress the PC3 cells growth in vitro. Clearly, it could be confirmed that HA-PEI coated Au/Fe3O4 nanoparticles with higher biocompatibility appear to be suitable for intracellular siRNA delivery.
- 19 October 2020
- Published by SAGE Publications in Journal of Bioactive and Compatible Polymers
- Vol. 35 (6) , 504-516
Polyethylenimine-coated gold-magnetic nanoparticles for ADAM10 siRNA delivery in prostate cancer cells
For an effective medical application of therapeutic siRNA, a safe and an efficient delivery system are required. Herein, magnetic nanoparticles (MNPs) have been successfully used as siRNA delivery vehicles. Firstly, MNPs were coated with gold (Au) nanoparticles and then capped with PEI. To improve the biocompatibility of nanoparticles, hyaluronic acid (HA) was coated onto the surface of PEI-Au/Fe nanoparticles. The prepared HA-PEI-Au/Fe3O4 nanoparticles were characterized and found to be uniform and well segregated in TEM analysis. FTIR analysis confirmed that HA was successfully conjugated to PEI. The polymer content in these nanoparticles was relatively higher than PEG coated nanoparticles. Cell viability assay demonstrated that the nanoparticles were relatively biocompatible in nature. ADAM10 siRNA was loaded into the HA-PEI-Au/Fe3O4 nanoparticles and cytotoxicity to prostate cancer (PC3) cells was analyzed. The results indicate that ADAM10 siRNA loaded HA-PEI-Au/Fe3O4 suppress the PC3 cells growth in vitro. Clearly, it could be confirmed that HA-PEI coated Au/Fe3O4 nanoparticles with higher biocompatibility appear to be suitable for intracellular siRNA delivery.
- Open Access
- 10 March 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (5) , 1895
Biopolymer-Based Microcarriers for Three-Dimensional Cell Culture and Engineered Tissue Formation
The concept of three-dimensional (3D) cell culture has been proposed to maintain cellular morphology and function as in vivo. Among different approaches for 3D cell culture, microcarrier technology provides a promising tool for cell adhesion, proliferation, and cellular interactions in 3D space mimicking the in vivo microenvironment. In particular, microcarriers based on biopolymers have been widely investigated because of their superior biocompatibility and biodegradability. Moreover, through bottom-up assembly, microcarriers have opened a bright door for fabricating engineered tissues, which is one of the cutting-edge topics in tissue engineering and regeneration medicine. This review takes an in-depth look into the recent advancements of microcarriers based on biopolymers—especially polysaccharides such as chitosan, chitin, cellulose, hyaluronic acid, alginate, and laminarin—for 3D cell culture and the fabrication of engineered tissues based on them. The current limitations and potential strategies were also discussed to shed some light on future directions.
- 10 March 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (5) , 1895
Open AccessBiopolymer-Based Microcarriers for Three-Dimensional Cell Culture and Engineered Tissue Formation
The concept of three-dimensional (3D) cell culture has been proposed to maintain cellular morphology and function as in vivo. Among different approaches for 3D cell culture, microcarrier technology provides a promising tool for cell adhesion, proliferation, and cellular interactions in 3D space mimicking the in vivo microenvironment. In particular, microcarriers based on biopolymers have been widely investigated because of their superior biocompatibility and biodegradability. Moreover, through bottom-up assembly, microcarriers have opened a bright door for fabricating engineered tissues, which is one of the cutting-edge topics in tissue engineering and regeneration medicine. This review takes an in-depth look into the recent advancements of microcarriers based on biopolymers—especially polysaccharides such as chitosan, chitin, cellulose, hyaluronic acid, alginate, and laminarin—for 3D cell culture and the fabrication of engineered tissues based on them. The current limitations and potential strategies were also discussed to shed some light on future directions.
- 9 August 2017
- Published by Springer Nature in Japanese Journal of Radiology
- Vol. 35 (10) , 555-561
Capacity of gold nanoparticles in cancer radiotherapy
Radiotherapy is the ionizing radiation used for treatment of cancer and other diseases. Although radiotherapy is the major treatment for cancer, a lot of patients do not undergo radiation due to associated risks such as radiation pneumonitis, cardiovascular complications, development of secondary tumor, and lymphedema. However, the advantages of nanotechnology provide a unique potential to enhance radiotherapeutic performance, in particular by utilizing gold nanoparticles (Au NPs). In this review, we briefly describe the current direction of research towards the use of Au NPs for radiotherapeutic enhancement, combination, monitoring and in side effect reductions.
- 9 August 2017
- Published by Springer Nature in Japanese Journal of Radiology
- Vol. 35 (10) , 555-561
Capacity of gold nanoparticles in cancer radiotherapy
Radiotherapy is the ionizing radiation used for treatment of cancer and other diseases. Although radiotherapy is the major treatment for cancer, a lot of patients do not undergo radiation due to associated risks such as radiation pneumonitis, cardiovascular complications, development of secondary tumor, and lymphedema. However, the advantages of nanotechnology provide a unique potential to enhance radiotherapeutic performance, in particular by utilizing gold nanoparticles (Au NPs). In this review, we briefly describe the current direction of research towards the use of Au NPs for radiotherapeutic enhancement, combination, monitoring and in side effect reductions.